Transmission of Mycobacterium tuberculosis in Child and Adolescent Contacts of Pulmonary Tuberculosis Patients in Brazil: A Multi-Center Prospective Cohort Analysis - Scorecard - MDSpire

Transmission of Mycobacterium tuberculosis in Child and Adolescent Contacts of Pulmonary Tuberculosis Patients in Brazil: A Multi-Center Prospective Cohort Analysis

  • By

  • Luciana Sobral

  • María B. Arriaga

  • Alexandra B. Souza

  • Beatriz Barreto-Duarte

  • Beatriz S. Garcia-Rosa

  • Catarina D. Fernandes

  • Artur T. L. Queiroz

  • Michael S. Rocha

  • Aline Benjamin

  • Adriana S. R. Moreira

  • Jamile G. de Oliveira

  • Anna Cristina C. Carvalho

  • Renata Spener-Gomes

  • Marina C. Figueiredo

  • Solange Cavalcante

  • Betina Durovni

  • José R. Lapa-e-Silva

  • Afrânio L. Kritski

  • Valeria C. Rolla

  • Timothy R. Sterling

  • Marcelo Cordeiro-Santos

  • Mariana Araújo-Pereira

  • Bruno B. Andrade

  • December 22, 2025

  • 0 min

Share

Clinical Scorecard: Transmission of Mycobacterium tuberculosis in Child and Adolescent Contacts of Pulmonary Tuberculosis Patients in Brazil: A Multi-Center Prospective Cohort Analysis

At a Glance

CategoryDetail
ConditionTuberculosis infection (TBI) in children and adolescents exposed to pulmonary TB patients
Key MechanismsTransmission of Mycobacterium tuberculosis primarily through close household contact with infectious pulmonary TB cases
Target PopulationChildren and adolescents (<18 years) who are close contacts of culture-confirmed pulmonary TB patients
Care SettingOutpatient and community-based screening and follow-up in Brazil, including clinical evaluation, IGRA testing, and preventive treatment

Key Highlights

  • Children exposed to active TB cases at home have nearly 4-fold increased risk of TB infection compared to unexposed peers.
  • IGRA testing (QuantiFERON-TB Gold Plus) was used to identify TB infection among contacts, with repeat testing at 6 months if initially negative.
  • TB preventive treatment (isoniazid 5-10 mg/kg for 6-9 months) is recommended for contacts with positive IGRA, age ≤5 years, or HIV infection.

Guideline-Based Recommendations

Diagnosis

  • Screen close contacts of pulmonary TB cases using IGRA or tuberculin skin test (TST).
  • IGRA preferred for its specificity and independence from BCG vaccination, requiring only one visit.
  • Consider IGRA testing in children over 3 years of age despite limited formal validation in under 5s.

Management

  • Initiate TB preventive treatment (TPT) for close contacts with positive IGRA, children ≤5 years, or HIV-infected individuals.
  • Recommended TPT regimen is isoniazid 5-10 mg/kg daily for 6 to 9 months.
  • Encourage clinical evaluation and treatment initiation regardless of study follow-up participation.

Monitoring & Follow-up

  • Repeat IGRA testing at 6 months for contacts initially IGRA-negative to detect conversion.
  • Conduct clinical follow-up every 6 months up to 24 months for TB symptoms.
  • Use chest X-ray and clinical evaluation at baseline and during follow-up as per national guidelines.

Risks

  • Young children under 5 years are at higher risk of severe TB forms and should be prioritized for preventive treatment.
  • Malnutrition and immature immune response may reduce sensitivity of diagnostic tests.
  • Not all household contacts become infected, indicating additional host, environmental, or pathogen factors influence transmission.

Patient & Prescribing Data

Children and adolescents who are close contacts of culture-confirmed pulmonary TB patients in Brazil

Isoniazid preventive therapy is effective and recommended for infected contacts and high-risk groups; adherence and completion are critical for prevention.

Clinical Best Practices

  • Identify and evaluate all close contacts with ≥4 hours/week exposure to pulmonary TB cases within prior 6 months.
  • Use IGRA testing preferentially for screening to improve specificity and reduce false positives related to BCG vaccination.
  • Provide TB preventive treatment promptly to eligible contacts, especially young children and those with positive IGRA.
  • Maintain longitudinal follow-up with clinical and immunological assessments to detect incident infections and active disease early.
  • Ensure informed consent and ethical conduct in all clinical investigations involving children and adolescents.

References

Original Source(s)

Related Content